Loading...
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatos...
Na minha lista:
| Udgivet i: | Theranostics |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ivyspring International Publisher
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4997239/ https://ncbi.nlm.nih.gov/pubmed/27570553 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.15311 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|